• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Alto Neuroscience preps IPO to push precision psychiatry therapies through the clinic

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Jan 16, 2024 at 09:42: AM
via As Alto Neuroscience’s machine learning-derived, biomarker-based depression therapies accrue positive phase 2 data, the company is planning to join the growing trickle of biotechs aiming to IPO in early 2024.

article source
 




Top Bottom
Back
Quote